- Supported exchanges /
- KQ /
- 284620.KQ
Kainos Medicine Inc (284620 KQ) stock market data APIs
Kainos Medicine, Inc. researches and develops various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. Kainos Medicine, Inc. was incorporated in 2007 and is headquartered in Seongnam-si, South Korea.
Kainos Medicine Inc Financial Data Overview
| 3440 | |
| 3655 | |
| - | |
| 3655 | |
| 3300 | |
| 2275-7100 | |
| 96 901 M | |
| 27 805 K | |
| 0 | |
| -86.9511 | |
| 1.165 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Kainos Medicine Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA 0
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Kainos Medicine Inc Earnings via APIs
- Latest Release 2024-09-30
- EPS/Forecast NaN
Get Kainos Medicine Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
